Sanofi $SNY Shares Bought by Teachers Retirement System of The State of Kentucky

Teachers Retirement System of The State of Kentucky raised its holdings in Sanofi (NASDAQ:SNY) by 8.3% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 443,390 shares of the company’s stock after purchasing an additional 34,100 shares during the quarter. Teachers Retirement System of The State of Kentucky’s holdings in Sanofi were worth $20,928,000 as of its most recent SEC filing.

Other large investors also recently added to or reduced their stakes in the company. Financial Consulate Inc. purchased a new stake in Sanofi during the 3rd quarter worth about $26,000. First Horizon Corp acquired a new stake in Sanofi during the 3rd quarter worth $33,000. Salomon & Ludwin LLC lifted its stake in Sanofi by 1,046.3% in the third quarter. Salomon & Ludwin LLC now owns 768 shares of the company’s stock valued at $39,000 after buying an additional 701 shares during the last quarter. Nisa Investment Advisors LLC boosted its stake in Sanofi by 233.3% during the 2nd quarter. Nisa Investment Advisors LLC now owns 1,000 shares of the company’s stock worth $48,000 after purchasing an additional 700 shares during the period. Finally, Traub Capital Management LLC acquired a new stake in shares of Sanofi during the second quarter worth about $51,000. 14.03% of the stock is currently owned by institutional investors and hedge funds.

Sanofi Price Performance

SNY opened at $46.47 on Wednesday. The company has a debt-to-equity ratio of 0.20, a quick ratio of 0.73 and a current ratio of 1.09. Sanofi has a 1-year low of $44.62 and a 1-year high of $60.12. The company has a 50-day moving average of $47.49 and a 200-day moving average of $48.55. The company has a market capitalization of $113.34 billion, a P/E ratio of 12.91, a PEG ratio of 1.23 and a beta of 0.45.

Analysts Set New Price Targets

Several brokerages have recently weighed in on SNY. Wall Street Zen downgraded shares of Sanofi from a “strong-buy” rating to a “buy” rating in a report on Saturday, February 21st. TD Cowen reiterated a “hold” rating on shares of Sanofi in a report on Tuesday, December 30th. Weiss Ratings reiterated a “hold (c)” rating on shares of Sanofi in a research note on Monday, December 29th. Guggenheim lowered shares of Sanofi from a “buy” rating to a “neutral” rating in a research report on Tuesday, December 9th. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating on shares of Sanofi in a report on Friday, January 16th. Five investment analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $62.67.

Sanofi Company Profile

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.